D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Phase 3
Not yet recruiting
- Conditions
- Biliary Tract Cancer (BTC)
- Interventions
- Drug: D07001-Softgel CapsulesDrug: PlaceboCombination Product: Capecitabine
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT06622057
- Locations
- ๐จ๐ณ
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- Drug: D07001-softgel capsules + Xeloda (or TS-1)Drug: mFOLFOX
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05065957
- Locations
- ๐จ๐ณ
National Taiwan University Hospotal, Taipei, Taiwan
๐จ๐ณKaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
๐จ๐ณTaipei Veterans General Hospital, Taipei, Taiwan
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
Phase 1
Completed
- Conditions
- Gastrointestinal CancerBiliary Tract Cancer
- Interventions
- Drug: D07001-softgel capsules
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03531320
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
๐จ๐ณNational Cheng-Kung University Hospital, Tainan, Taiwan
๐จ๐ณChina Medical University Hospital, Taichung, Taiwan
Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
Phase 1
Completed
- Conditions
- Advanced Solid MalignanciesMalignant Lymphomas
- Interventions
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01800630
- Locations
- ๐จ๐ณ
National Cheng Kung University Hospital, Tainan, Taiwan
๐จ๐ณNational Taiwan University Hospital, Taipei, Taiwan
๐จ๐ณTaipei Veterans General Hospital, Taipei, Taiwan
An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- InnoPharmax Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01678690
- Locations
- ๐บ๐ธ
Georgia Regents University- Cancer Center, Augusta, Georgia, United States
๐บ๐ธGabrail Cancer Center Research, Dover, Ohio, United States
๐จ๐ณNational Taiwan University Hospital, Taipei, Taiwan
ยฉ Copyright 2025. All Rights Reserved by MedPath